Trial Profile
A phase I clinical study to evaluate the safety of a single injection of REMD-477 (AMG477) in healthy volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Nov 2015
Price :
$35
*
At a glance
- Drugs Volagidemab (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- 23 Nov 2015 New trial record
- 19 Nov 2015 Results published in a REMD Biotherapeutics media release.